FDA clears IS2’s NuCammas

Article

Canadian gamma camera manufacturer IS2 Research reported this month that the Food and Drug Administration has cleared its two digital single-head gamma cameras for commercialization. The cameras, NuCamma C+ and NuCamma Rx, were designed by

Canadian gamma camera manufacturer IS2 Research reported this month that the Food and Drug Administration has cleared its two digital single-head gamma cameras for commercialization. The cameras, NuCamma C+ and NuCamma Rx, were designed by founder Iain Stark, formerly of Park Medical. They were introduced at this year’s Society of Nuclear Medicine meeting (SCAN 8/5/98).

NuCamma C+ has a circular field of view, while NuCamma Rx is a rectangular system. The electronics of both units are incorporated into their detectors, and the systems will carry list prices between $150,000 and $190,000. The Nepean, Ontario-based company has almost completed the manufacturing of its first batch of 10 cameras.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.